Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Grows Slow, Awaits Helsinki Presentation

The first trading session after Labor Day Weekend was iffy for Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS). The ticker was bought and sold, finally ending up just 1.3% to $0.075, on volumes above $1.48 million.

AMBS decided to remind of itself with a mention of upcoming commercialization of one of its drugs. The event itself is far off- but the company hired a new advisor to boost the process. Dr. Colin Bier would join the corporate advisory board, with still unknown results except for the fact that the company is again in the news.

AMBS saw only a limited promotion with a $5,500 budget. But like other pharmaceutical companies that show interesting developments, this ticker may find itself in the spotlight again.

Pharmaceutical companies often manage to extract long-term interest for investors, as often these firms come up with hopeful and fast developments, or attract a good buyout offer. But a piece of bad news could wreck all that, wiping out value from stocks in matter of days. Currently, investor sentiment expressed over message boards points toward a general distrust of AMBS, and that the current levels are already overrated.

And now long-term sinker Advanced Cell Technology, Inc. (OTCBB:ACTC) is making a little comeback, returning above 6 cents after adding 2.39% on volumes of $303,000. NanoViricides, Inc. (OTCMKTS:NNVC) is calming down for now, at $1.25 after adding about 3%.

AMBS now awaits the Helsinki biotech conference, where it will make a presentation- but we cannot be sure if it would be a run of the mill profile of the company, or if significant news would be revealed. Still, the next two days should come with comments from the company, and any exposure would boost activity.

At this time, the pumper Titan Stock Alerts is trying to revive an old and much-touted ticker, NanoLabs, Corp. (OTCBB:CTLE). The stock bottomed out around 5 cents, and now the new promotion may cause a rebounce, and an attempt to revisit recent higher positions.

AMBS has slowed down its growth in the past days, and a downturn after such a long trend is not out of the question. Still, at only 7 cents, the stock is accessible enough. But if you need to take this pharmaceutical ticker on board, it is best to invest only sums that you can afford to lose.